Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 12

1.

Solitary cystic cerebellar metastasis in a patient with invasive transitional cell carcinoma of the bladder.

Vaa B, Kohli M, Price KA, Swetz KM.

BMJ Case Rep. 2014 Jun 11;2014. pii: bcr2013200137. doi: 10.1136/bcr-2013-200137.

PMID:
24920508
[PubMed - in process]
2.

Acinic cell carcinoma of the salivary gland with metastatic spread to the pancreas.

Geiger JL, GarcĂ­a JJ, Price KA.

Case Rep Oncol. 2014 Mar 13;7(1):195-8. doi: 10.1159/000360395. eCollection 2014 Jan.

PMID:
24748870
[PubMed]
Free PMC Article
3.

Adjuvant chemoradiation therapy with high-dose versus weekly cisplatin for resected, locally-advanced HPV/p16-positive and negative head and neck squamous cell carcinoma.

Geiger JL, Lazim AF, Walsh FJ, Foote RL, Moore EJ, Okuno SH, Olsen KD, Kasperbauer JL, Price DL, Garces YI, Ma DJ, Neben-Wittich MA, Molina JR, Garcia JJ, Price KA.

Oral Oncol. 2014 Apr;50(4):311-8. doi: 10.1016/j.oraloncology.2014.01.001. Epub 2014 Jan 24.

PMID:
24467937
[PubMed - in process]
4.

Phase II trial of neoadjuvant bevacizumab plus chemotherapy and adjuvant bevacizumab in patients with resectable nonsquamous non-small-cell lung cancers.

Chaft JE, Rusch V, Ginsberg MS, Paik PK, Finley DJ, Kris MG, Price KA, Azzoli CG, Fury MG, Riely GJ, Krug LM, Downey RJ, Bains MS, Sima CS, Rizk N, Travis WD, Rizvi NA.

J Thorac Oncol. 2013 Aug;8(8):1084-90. doi: 10.1097/JTO.0b013e31829923ec.

PMID:
23857398
[PubMed - indexed for MEDLINE]
5.

Risk of hemoptysis in patients with resected squamous cell and other high-risk lung cancers treated with adjuvant bevacizumab.

Hellmann MD, Chaft JE, Rusch V, Ginsberg MS, Finley DJ, Kris MG, Price KA, Azzoli CG, Fury MG, Riely GJ, Krug LM, Downey RJ, Bains MS, Sima CS, Rizk N, Travis WD, Rizvi NA, Paik PK.

Cancer Chemother Pharmacol. 2013 Aug;72(2):453-61. doi: 10.1007/s00280-013-2219-5. Epub 2013 Jun 28.

PMID:
23811982
[PubMed - indexed for MEDLINE]
6.

Oropharyngeal cancer biology and treatment: insights from messenger RNA sequence analysis and transoral robotic surgery.

Foote RL, Garces YI, Neben Wittich MA, Ma DJ, Park SS, Molina JR, Okuno SH, Price KA, Schild SE, Patel SH.

Mayo Clin Proc. 2012 Nov;87(11):1132; author reply 1132-3. doi: 10.1016/j.mayocp.2012.08.007. No abstract available.

PMID:
23127739
[PubMed - indexed for MEDLINE]
Free PMC Article
7.

Phase II study of the multitargeted tyrosine kinase inhibitor XL647 in patients with non-small-cell lung cancer.

Pietanza MC, Gadgeel SM, Dowlati A, Lynch TJ, Salgia R, Rowland KM Jr, Wertheim MS, Price KA, Riely GJ, Azzoli CG, Miller VA, Krug LM, Kris MG, Beumer JH, Tonda M, Mitchell B, Rizvi NA.

J Thorac Oncol. 2012 May;7(5):856-65. doi: 10.1097/JTO.0b013e31824c943f.

PMID:
22722787
[PubMed - indexed for MEDLINE]
8.

Current treatment options for metastatic head and neck cancer.

Price KA, Cohen EE.

Curr Treat Options Oncol. 2012 Mar;13(1):35-46. doi: 10.1007/s11864-011-0176-y. Review.

PMID:
22252884
[PubMed - indexed for MEDLINE]
9.

Phase II trial of gefitinib and everolimus in advanced non-small cell lung cancer.

Price KA, Azzoli CG, Krug LM, Pietanza MC, Rizvi NA, Pao W, Kris MG, Riely GJ, Heelan RT, Arcila ME, Miller VA.

J Thorac Oncol. 2010 Oct;5(10):1623-9. doi: 10.1097/JTO.0b013e3181ec1531.

PMID:
20871262
[PubMed - indexed for MEDLINE]
Free PMC Article
10.

Hydration in cancer patients.

Price KA.

Curr Opin Support Palliat Care. 2010 Dec;4(4):276-80. doi: 10.1097/SPC.0b013e32833e48d1. Review.

PMID:
20693908
[PubMed - indexed for MEDLINE]
11.

Advances in treatment for non-small cell lung cancer.

Price KA, Jett JR.

Int J Tuberc Lung Dis. 2010 Jul;14(7):792-4. No abstract available.

PMID:
20550759
[PubMed - indexed for MEDLINE]
12.

Chemoradiation for unresectable stage III non-small cell lung cancer.

Price KA, Azzoli CG, Gaspar LE.

Semin Thorac Cardiovasc Surg. 2008 Fall;20(3):204-9. doi: 10.1053/j.semtcvs.2008.09.007. Review.

PMID:
19038729
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk